Abstract
The activation of an inducible caspase (iCaspase-9) mediates apoptosis of neovascular endothelial cells, and overcomes the prosurvival effect of vascular endothelial growth factor or basic fibroblast growth factor. The potential utilization of direct activation of caspases as an antiangiogenic strategy for treatment of angiogenesis-dependent diseases (eg cancer) requires expression of the inducible caspase primarily in the tumor endothelium. The objective of this work was to develop and characterize a transcriptionally targeted adenoviral vector that mediates expression of iCaspase-9 specifically in neovascular endothelial cells. We observed that adenoviral vectors containing the human VEGFR2 promoter induced reporter gene expression primarily in proliferating human dermal microvascular endothelial cells (HDMEC). HDMEC transduced with recombinant adenoviral vectors containing iCaspase-9 under regulation of the VEGFR2 promoter (Ad-hVEGFR2-iCaspase-9) and exposed to a cell-permeable dimerizer drug (AP20187), presented higher caspase-3 activity and apoptosis than controls (P⩽0.05). Using the SCID Mouse Model of Human Angiogenesis, we observed that local delivery of Ad-hVEGFR2-iCaspase-9 followed by intraperitoneal injection of AP20187 resulted in endothelial cell apoptosis and local ablation of microvessels. We believe that this constitutes the first report of a transcriptionally targeted antiangiogenic adenoviral vector that mediates neovascular disruption upon activation of a caspase-based artificial death switch.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–1186.
Bouck N, Stellmach V, Hsu SC . How tumors become angiogenic. Adv Cancer Res 1996; 69: 135–174.
Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–364.
Folkman J . Angiogenesis and angiogenesis inhibition: an overview. EXS 1997; 79: 1–8.
Gerber HP et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336–30343.
Nör JE, Polverini PJ . Role of endothelial cell survival and death signals in angiogenesis. Angiogenesis 1999a; 3: 101–116.
Nör JE et al. Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001a; 61: 2183–2188.
Araki S, Simada Y, Kaji K, Hayashi H . Role of protein kinase C in the inhibition by fibroblast growth factor of apoptosis in serum-depleted endothelial cells. Biochem Biophys Res Commun 1990; 172: 1081–1085.
Nör JE et al. Ablation of microvessels in vivo upon dimerization of iCaspase-9. Gene Therapy 2002; 9: 444–451.
Ali M, Lemoine NR, Ring CJ . The use of DNA viruses as vectors for gene therapy. Gene Therapy 1994; 1: 367–384.
St George JA . Gene therapy progress and prospects: adenoviral vectors. Gene Therapy 2003; 10: 1135–1141.
Latham JP, Searle PF, Mautner V, James ND . Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000; 60: 334–341.
Xie X et al. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res 2001; 61: 6795–6804.
Wickham TJ . Targeting adenovirus. Gene Therapy 2000; 7: 110–114.
Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR . Controlling signal transduction with synthetic ligands. Science 1993; 262: 1019–1024.
Singhal S, Kaiser LR . Cancer chemotherapy using suicide genes. Surg Oncol Clin N Am 1998; 7: 505–536.
Fan L et al. Improved artificial death switches based on caspases and FADD. Hum Gene Ther 1999; 10: 2273–2285.
Patterson C et al. Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. J Biol Chem 1995; 270: 23111–23118.
Millauer B et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996; 56: 1615–1620.
Heidenreich R, Kappel A, Breier G . Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (Flk-1) promoter/enhancer sequences. Cancer Res 2000; 60: 6142–6147.
Jaggar RT, Chan HY, Harris AL, Bicknell R . Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery. Hum Gene Ther 1997; 8: 2239–2247.
Modlich U, Pugh CW, Bicknell R . Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Therapy 2000; 7: 896–902.
MacCorkle RA, Freeman KW, Spencer DM . Synthetic activation of caspases: artificial death switches. Proc Natl Acad Sci USA 1998; 95: 3655–3660.
Shariat SF et al. Adenovirus-mediated transfer of inducible caspases: a novel ‘death switch’ gene therapeutic approach to prostate cancer. Cancer Res 2001; 61: 2562–2571.
Quinn TP et al. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 1993; 90: 7533–7537.
Nör JE et al. Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 2001b; 81: 453–463.
Clackson T . Redesigning small molecule-protein interfaces. Curr Opin Struct Biol 1998; 8: 451–458.
Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31.
Folkman J . Fighting cancer by attacking its blood supply. Sci Am 1996; 275: 150–154.
Plate KH et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993; 53: 5822–5827.
Korhonen J et al. Endothelial-specific gene expression directed by the tie gene promoter in vivo. Blood 1995; 86: 1828–1835.
Schlaeger TM et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci USA 1997; 94: 3058–3063.
Dejana E, Bazzoni G, Lampugnani MG . Vascular endothelial (VE)-cadherin: only an intercellular glue? Exp Cell Res 1999; 252: 13–19.
Kappel A et al. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 1999; 93: 4284–4292.
Nör JE, Christensen J, Mooney DJ, Polverini PJ . Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999b; 154: 375–384.
Acknowledgements
We thank Ruben Hernandez-Alcoceba for help in designing the adenovirus vectors; Michael Clarke for helpful discussions and for critical review of this manuscript; Victor Rivera for critical review of this manuscript; and John Westman and Chris Strayhorn for help with the histology. We also thank ARIAD Pharmaceuticals (www.ariad.com/regulationkits) for the dimerizing agent AP20187. This research was supported in part by Grant DE14601 from NIH, and grant from the American Dental Association Health Foundation (JEN); Grants CA70057 (GN) and CA77266 (DMS) from the NIH; and by Grant 2 P30 CA46592-14 from NIH to the University of Michigan Comprehensive Cancer Center.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Song, W., Sun, Q., Dong, Z. et al. Antiangiogenic gene therapy: disruption of neovascular networks mediated by inducible caspase-9 delivered with a transcriptionally targeted adenoviral vector. Gene Ther 12, 320–329 (2005). https://doi.org/10.1038/sj.gt.3302306
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302306
Keywords
This article is cited by
-
In silico database screening of potential targets and pathways of compounds contained in plants used for psoriasis vulgaris
Archives of Dermatological Research (2015)
-
The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting
Laboratory Investigation (2014)
-
Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells
Cancer Gene Therapy (2008)
-
Gene therapy targeting to tumor endothelium
Cancer Gene Therapy (2007)